Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Modafinil in Multiple Sclerosis

This study has been completed.
National Multiple Sclerosis Society
Information provided by (Responsible Party):
Nancy Chiaravalloti, Kessler Foundation Identifier:
First received: September 1, 2005
Last updated: September 25, 2013
Last verified: September 2013

Deficits in new learning and memory in MS are a major complaint of patients, and have been noted to be a significant contributor to disability by numerous researchers. Modafinil is a psychostimulant medication, FDA approved for the treatment of Narcolepsy, with potential application for the treatment of learning and memory dysfunction in MS. This randomized clinical trial tests the efficacy of Modafinil for the treatment of new learning and memory deficits in MS.

Twenty subjects with clinically definite MS and objectively documented new learning impairment will be included in the study. All subjects will undergo baseline neuropsychological testing and EDSS to document current levels of functioning in new learning and memory abilities. Subjects will then be randomly assigned to either group 1 or group 2. Group 1 (n=10) will first undergo treatment with Modafinil (200 mg once per day in the morning) for 2 weeks. They will then undergo follow-up neuropsychological assessment and follow-up EDSS to evaluate any medication effects. After the follow-up evaluation, there will be a washout period of one week in which no medication will be administered. Group 1 will then receive a placebo medication for 2 weeks. A second follow-up evaluation will be conducted following this latter arm of the study. Group 2 (n=10) will follow the same pattern, but will receive the placebo medication during the first arm of the study and Modafinil during the 2nd arm of the study. The subjects and the experimenter administering the neuropsychological evaluation will be blind to group membership.

Condition Intervention
Multiple Sclerosis
Drug: Modafinil

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Modafinil for Improving New Learning and Memory in Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Kessler Foundation:

Primary Outcome Measures:
  • Scores on memory tests at 3 weeks and 6 weeks

Secondary Outcome Measures:
  • Scores on fatigue measures at 3 weeks and 6 weeks
  • Scores on emotional measures at 3 weeks and 6 weeks

Estimated Enrollment: 20
Study Start Date: June 2003
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must understand English, diagnosis of Multiple Sclerosis

Exclusion Criteria:

  • Significant language comprehension deficits, age greater than 60, less than 1-month post most recent exacerbation, current treatment with corticosteroids, significant neurological history aside from MS (e.g. epilepsy, TBI), significant substance abuse history as documented by the MAST,27 significant psychiatric history (e.g. Schizophrenia, Bipolar Disorder, Major Depression), non-fluency in the English language.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00142402

United States, New Jersey
Kessler Foundation
West Orange, New Jersey, United States, 07052
Sponsors and Collaborators
Kessler Foundation
National Multiple Sclerosis Society
Principal Investigator: Nancy D Chiaravalloti, PhD KMRREC
  More Information

No publications provided

Responsible Party: Nancy Chiaravalloti, Director, Kessler Foundation Identifier: NCT00142402     History of Changes
Other Study ID Numbers: ndcnmss2004, PP0911
Study First Received: September 1, 2005
Last Updated: September 25, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Kessler Foundation:
Multiple Sclerosis
New Learning

Additional relevant MeSH terms:
Multiple Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Central Nervous System Agents
Central Nervous System Stimulants
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Wakefulness-Promoting Agents processed this record on November 25, 2014